Premium
Bismuth‐containing single‐antibiotic 1‐week triple therapy for Helicobacter pylori eradication
Author(s) -
Alexander P. Scott
Publication year - 1998
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1046/j.1365-2036.1998.00296.x
Subject(s) - medicine , lansoprazole , helicobacter pylori , clarithromycin , gastroenterology , regimen , proton pump inhibitor , vomiting , nausea , breath test , antibiotics , urea breath test , helicobacter pylori infection , microbiology and biotechnology , biology
Background: Although bismuth was both the first drug shown to alter the natural history of peptic ulcer disease and also a constituent of the first very effective eradication regimens, it has been excluded from the newer regimens, despite its safety and low cost, in favour of two antibiotics. Aim: To asses a novel 1‐week regimen consisting of bismuth, clarithromycin and a proton pump inhibitor in routine clinical practice. Methods: One hundred and three consecutive patients with peptic ulcer disease and antral biopsies containing Helicobacter pylori were given a 7‐day course of treatment with bismuth (tripotassium dicitrato bismuthate chelate) 120 mg q.d.s., clarithromycin 500 mg t.d.s. and lansoprazole 30 mg o.d. Completeness of eradication was assessed by a 13 C‐urea breath test, in all except three patients, at least 4 months later. Results: Of the 100 patients who were assessed in this open treatment study 84 (84%; 95% CI: 77–91%) had a negative breath test. Minor side‐effects were reported by 14% and more troublesome side‐effects (nausea, vomiting, diarrhoea, hallucinations, nasty taste and body pains) were reported by 10%. Conclusions: A 1‐week course of triple therapy including bismuth, clarithromycin and a proton pump inhibitor is effective in routine clinical practice and is well tolerated.